<DOC>
	<DOCNO>NCT00277290</DOCNO>
	<brief_summary>This clinical trial conduct multiple site evaluate activity , safety , tolerability XL999 give weekly patient ovarian cancer previously treat platinum-based chemotherapy . XL999 small molecule inhibitor multiple kinase include VEGFR , PDGFR , FGFR , FLT-3 , Src , involve tumor cell growth , formation new blood vessel ( angiogenesis ) , metastasis .</brief_summary>
	<brief_title>Study XL999 Patients With Previously Treated Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<criteria>Female patient histologically confirm diagnosis metastatic ovarian cancer Measurable disease accord Response Criteria Solid Tumors ( RECIST ) Prior treatment platinumbased therapy Platinumsensitive platinumresistant disease Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Life expectancy ≥3 month Adequate organ marrow function Signed inform consent No malignancy within 5 year Radiation ≥25 % bone marrow within 30 day XL999 treatment Use investigational drug cytotoxic chemotherapy within 30 day XL999 treatment Prior anticancer therapy target VEGF ( eg , bevacizumab , sorafenib , sunitinib ) More two prior systemic nonplatinum cytotoxic chemotherapy regimens Subject recover grade ≤1 within 10 % baseline adverse event due medication administer &gt; 30 day prior study enrollment History know brain metastasis , current spinal cord compression , carcinomatous meningitis Uncontrolled and/or intercurrent illness Patients pregnant breastfeed Known human immunodeficiency virus ( HIV )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Recurrent</keyword>
	<keyword>Platinum-resistant</keyword>
	<keyword>Platinum-sensitive</keyword>
</DOC>